AR096759A1 - Formas sólidas de un inhibidor de quinasa macrocíclica - Google Patents
Formas sólidas de un inhibidor de quinasa macrocíclicaInfo
- Publication number
- AR096759A1 AR096759A1 ARP140102433A ARP140102433A AR096759A1 AR 096759 A1 AR096759 A1 AR 096759A1 AR P140102433 A ARP140102433 A AR P140102433A AR P140102433 A ARP140102433 A AR P140102433A AR 096759 A1 AR096759 A1 AR 096759A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystalline
- benzoxadiazacyclotetradecin
- pyrazolo
- carbonitrile
- tetrahydro
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 239000012453 solvate Substances 0.000 abstract 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 2
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361840703P | 2013-06-28 | 2013-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096759A1 true AR096759A1 (es) | 2016-02-03 |
Family
ID=51136530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102433A AR096759A1 (es) | 2013-06-28 | 2014-06-26 | Formas sólidas de un inhibidor de quinasa macrocíclica |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9637500B2 (enExample) |
| EP (1) | EP3013835B1 (enExample) |
| JP (1) | JP6110817B2 (enExample) |
| AR (1) | AR096759A1 (enExample) |
| CA (1) | CA2916605C (enExample) |
| ES (1) | ES2656189T3 (enExample) |
| TW (1) | TW201504246A (enExample) |
| WO (1) | WO2014207606A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016026423A1 (en) * | 2014-08-20 | 2016-02-25 | Teligene Ltd | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| EP3183256A4 (en) * | 2014-08-20 | 2018-05-30 | Teligene Ltd. | Substituted macrocycles useful as kinases inhibitors and methods of use thereof |
| CN116063322A (zh) | 2015-07-31 | 2023-05-05 | 辉瑞公司 | 劳拉替尼游离碱的结晶形式 |
| CA3000386A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| WO2017148325A1 (zh) * | 2016-03-03 | 2017-09-08 | 深圳市塔吉瑞生物医药有限公司 | 一种大环化合物及包含该化合物的组合物 |
| JP2019510774A (ja) * | 2016-04-08 | 2019-04-18 | ファイザー・インク | ロルラチニブマレイン酸塩の結晶質形態 |
| FI3694863T3 (fi) * | 2017-10-10 | 2023-08-18 | Pfizer | Lorlatinibin vapaan emäksen hydraatin kidemuoto |
| US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
| EP3784675A1 (en) | 2018-04-23 | 2021-03-03 | Pliva Hrvatska D.O.O. | Solid state forms of lorlatinib and their preparation |
| CN111233833A (zh) * | 2018-11-28 | 2020-06-05 | 深圳市塔吉瑞生物医药有限公司 | 一种氘代大环化合物的制备方法 |
| CN109651398B (zh) * | 2019-01-25 | 2021-07-30 | 安庆多辉生物科技有限公司 | 一种合成劳拉替尼的溴代物中间体及催化合成劳拉替尼的方法 |
| US12391708B2 (en) | 2019-07-18 | 2025-08-19 | Tapi Croatia Industries Ltd | Crystalline Lorlatinib : fumaric acid and solid state form thereof |
| CN112321604A (zh) * | 2019-08-05 | 2021-02-05 | 华东理工大学 | 大环类jak2抑制剂及其应用 |
| CN110483551B (zh) * | 2019-08-30 | 2021-10-22 | 北京赛思源生物医药技术有限公司 | 一种劳拉替尼游离碱的晶体 |
| WO2021069571A1 (en) | 2019-10-10 | 2021-04-15 | Sandoz Ag | Polymorph of lorlatinib |
| CN112824417A (zh) * | 2019-11-21 | 2021-05-21 | 上海天慈国际药业有限公司 | 一种劳拉替尼的制备方法 |
| WO2021176349A1 (en) | 2020-03-05 | 2021-09-10 | Pfizer Inc. | Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor |
| KR20240132391A (ko) | 2020-05-05 | 2024-09-03 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| KR102698413B1 (ko) | 2020-05-05 | 2024-08-26 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| CN112724077B (zh) * | 2020-12-29 | 2023-07-11 | 武汉利昌医药科技有限公司 | 一种劳拉替尼中间体的合成方法 |
| CN113292496B (zh) * | 2021-05-17 | 2023-03-10 | 安徽联创生物医药股份有限公司 | 一种劳拉替尼中间体的合成方法 |
| IL311444A (en) | 2021-10-01 | 2024-05-01 | Nuvalent Inc | Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| WO2013132376A1 (en) | 2012-03-06 | 2013-09-12 | Pfizer Inc. | Macrocyclic derivatives for the treatment of proliferative diseases |
-
2014
- 2014-06-17 EP EP14736454.1A patent/EP3013835B1/en not_active Not-in-force
- 2014-06-17 US US14/898,582 patent/US9637500B2/en active Active
- 2014-06-17 ES ES14736454.1T patent/ES2656189T3/es active Active
- 2014-06-17 WO PCT/IB2014/062296 patent/WO2014207606A1/en not_active Ceased
- 2014-06-17 CA CA2916605A patent/CA2916605C/en active Active
- 2014-06-18 JP JP2014124999A patent/JP6110817B2/ja not_active Expired - Fee Related
- 2014-06-26 AR ARP140102433A patent/AR096759A1/es unknown
- 2014-06-27 TW TW103122400A patent/TW201504246A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2916605A1 (en) | 2014-12-31 |
| EP3013835B1 (en) | 2017-12-13 |
| JP6110817B2 (ja) | 2017-04-05 |
| TW201504246A (zh) | 2015-02-01 |
| US20160115178A1 (en) | 2016-04-28 |
| US9637500B2 (en) | 2017-05-02 |
| JP2015010091A (ja) | 2015-01-19 |
| ES2656189T3 (es) | 2018-02-26 |
| EP3013835A1 (en) | 2016-05-04 |
| CA2916605C (en) | 2018-04-24 |
| WO2014207606A1 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019268062A1 (en) | Benzoquinolone inhibitors of VMAT2 | |
| UY33503A (es) | Imidazo [1,2-a]pirimidinas y piridinas sustituidas | |
| AR090151A1 (es) | Compuestos inhibidores de raf | |
| IN2015DN01156A (enExample) | ||
| IL246028A0 (en) | Compounds 2 - amino - 6 - fluoro - n - [ - fluoro - pyridine - 3 yl] pyrazolo (1, 5 - a ) pyrimidine - 3 - carboxamide, their solid forms, preparations containing them and methods for their preparation | |
| PH12015502814A1 (en) | 4-membered ring carboxamides used as nematicides | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2015002516A1 (es) | Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y métodos de uso | |
| IN2014MN02657A (enExample) | ||
| IN2014MN02658A (enExample) | ||
| PY1432622A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
| PH12013500870A1 (en) | Heterocyclic compounds and uses thereof | |
| ES2570569T3 (es) | Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso | |
| MX2016002117A (es) | Nuevos derivados de triazolo[4,5-d]pirimidina. | |
| JOP20140141B1 (ar) | استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية | |
| IN2014MN02497A (enExample) | ||
| NZ711718A (en) | Substituted xanthines and methods of use thereof | |
| CL2015002060A1 (es) | Compuestos. | |
| CL2016000241A1 (es) | Formulación de inhibidores de la syk. | |
| MX2016007176A (es) | Composiciones y metodos para obtener (r)-reticulina y precursores de las misma. | |
| BR112015028770A2 (pt) | composição de polipropileno duro adequada para pintura sem base | |
| EA201401062A1 (ru) | Бициклические пиразиноновые производные | |
| PH12013500942A1 (en) | Triazolopyridine compounds | |
| BR112017028604A2 (pt) | forma cristalina de base livre de lorlatinibe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |